title: A double-blind, randomized, controlled trial of topical polysporin triple compound versus topical mupirocin for the eradication of colonization with methicillin-resistant Staphylococcus aureus in a complex continuing care population.
abstract: BACKGROUND
  Intranasal mupirocin or Polysporin Triple (PT) ointment (polymyxin B, bacitracin, gramicidin), in combination with chlorhexidine body washes, have been used for eradicating methicillin-resistant Staphylococcus aureus (MRSA), but no comparative studies have been done.
  
  
  METHODS
  A double-blind, randomized, controlled clinical trial to compare the efficacy of mupirocin versus PT ointment in combination with chlorhexidine body washes in eradicating MRSA carriage was conducted. Asymptomatic MRSA carriers, medically stable and at least 18 years of age who were patients on medical wards, received twice daily application of either mupirocin or PT ointment to the anterior nares plus once daily 2% chlorhexidine body washes for seven days. Follow-up swabs from multiple sites using broth enrichment were conducted at 48 h, and one, two, four, eight and 12 weeks.
  
  
  RESULTS
  Of 103 patients eligible for analysis (54 mupirocin; 49 PT), no significant differences between the two groups with respect to baseline demographics, risk factors for MRSA or MRSA colonization sites were noted. At 48 h, 35 of 54 (65%) patients in the mupirocin group versus 15 of 49 (31%) in the PT group (P=0.001) were found to be MRSA negative at all sites. Significant differences were observed at one and two weeks but were not maintained at other intervals. In those with complete microbiological follow-up, MRSA eradication at all sites occurred in 12 of 39 (30.8%) mupirocin- and one of 36 (2.8%) PT-treated patients (P=0.001).
  
  
  CONCLUSIONS
  Both agents demonstrated poor efficacy and PT was significantly less efficacious than mupirocin at 12 weeks in eradicating MRSA from all sites.
authors.affiliation: Bridgepoint Health;
authors.forename: S
authors.initials: S
authors.lastname: O'Grady
authors.forename: Z
authors.initials: Z
authors.lastname: Hirji
authors.forename: B
authors.initials: B
authors.lastname: Pejcic-Karapetrovic
authors.forename: S
authors.initials: S
authors.lastname: Fung
authors.forename: H
authors.initials: H
authors.lastname: Dedier
authors.forename: J
authors.initials: J
authors.lastname: Takata-Shewchuk
authors.forename: K
authors.initials: K
authors.lastname: Zhang
authors.forename: J
authors.initials: J
authors.lastname: Conly
references.citation: Perit Dial Int. 2001 Nov-Dec;21(6):554-9
references.pmid: 11783763
references.citation: Infect Control Hosp Epidemiol. 2007 Sep;28(9):1036-43
references.pmid: 17932823
references.citation: J Infect Dis. 2002 Sep 1;186(5):652-60
references.pmid: 12195352
references.citation: CMAJ. 2001 Nov 13;165(10):1339-41
references.pmid: 11760981
references.citation: J Hosp Infect. 2001 Aug;48 Suppl A:S9-14
references.pmid: 11759035
references.citation: N Engl J Med. 1998 Aug 20;339(8):520-32
references.pmid: 9709046
references.citation: Infect Control Hosp Epidemiol. 2001 Aug;22(8):505-9
references.pmid: 11700878
references.citation: Gerontologist. 1970 Spring;10(1):20-30
references.pmid: 5420677
references.citation: Infect Control Hosp Epidemiol. 2000 Oct;21(10):653-5
references.pmid: 11083183
references.citation: Infect Control Hosp Epidemiol. 2001 Mar;22(3):152-6
references.pmid: 11310693
references.citation: Infect Control Hosp Epidemiol. 2001 Sep;22(9):578-80
references.pmid: 11732789
references.citation: J Am Soc Nephrol. 2003 Jan;14(1):169-79
references.pmid: 12506149
references.citation: J Antimicrob Chemother. 1998 Nov;42(5):577-83
references.pmid: 9848440
references.citation: J Hosp Infect. 1998 Aug;39(4):253-90
references.pmid: 9749399
references.citation: J Clin Microbiol. 2001 Oct;39(10):3481-5
references.pmid: 11574559
references.citation: Clin Infect Dis. 2007 Jan 15;44(2):178-85
references.pmid: 17173213
references.citation: Infect Control Hosp Epidemiol. 1996 Dec;17(12):811-3
references.pmid: 8985769
references.citation: Infect Control Hosp Epidemiol. 1996 Dec;17(12):775-9
references.pmid: 8985762
references.citation: Am J Med. 1999 May 3;106(5A):2S-10S; discussion 48S-52S
references.pmid: 10348058
references.citation: Am J Med. 1993 Apr;94(4):371-8
references.pmid: 8475930
references.citation: J Antimicrob Chemother. 1988 Sep;22(3):377-84
references.pmid: 3141347
references.citation: Infect Control Hosp Epidemiol. 2003 May;24(5):362-86
references.pmid: 12785411
references.citation: Infect Control Hosp Epidemiol. 2000 Jul;21(7):459-64
references.pmid: 10926396
references.citation: Clin Infect Dis. 2003 Oct 1;37(7):933-8
references.pmid: 13130405
references.citation: Infect Control Hosp Epidemiol. 1996 Jan;17(1):20-8
references.pmid: 8789683
references.citation: Infect Control Hosp Epidemiol. 1996 Dec;17(12):813-6
references.pmid: 8985770
references.citation: Lancet. 1997 Dec 6;350(9092):1670-3
references.pmid: 9400512
references.citation: J Clin Microbiol. 2005 Oct;43(10):5026-33
references.pmid: 16207957
references.citation: J Clin Microbiol. 2004 Nov;42(11):4947-55
references.pmid: 15528678
references.citation: N Engl J Med. 2001 Jan 4;344(1):11-6
references.pmid: 11136954
references.citation: Antimicrob Agents Chemother. 1999 Jun;43(6):1412-6
references.pmid: 10348762
references.citation: Clin Microbiol Rev. 1997 Jul;10(3):505-20
references.pmid: 9227864